
In the face of the significant challenges posed by the SARS-CoV-2 pandemic, particularly the strain it places on healthcare capacity and the health of frontline workers, the potential of the Bacillus Calmette-Guérin (BCG) vaccine to offer protection has emerged. A placebo-controlled, multi-centre randomized trial will enrol 1800 high-risk individuals, including those with comorbidities, healthcare workers, and first responders, with a 1:1 randomization to receive either intradermal BCG or a placebo (saline). Additionally, a cognitive function and brain imaging sub-study will be conducted. The trial's primary aim is to assess whether BCG vaccination can reduce the impact of SARS-CoV-2 infection in high-risk populations.
Like
Save
Share